Literature DB >> 6984355

Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.

T J Eberlein, M Rosenstein, P Spiess, R Wesley, S A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6984355     DOI： 10.1007/BF00200194

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  46 in total

1.  In vivo effects of lymphocytes sensitized in vitro against tumor cells.

Authors:  A J Treves; I R Cohen; B Schechter; M Feldman
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

2.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

Review 3.  Passive immunotherapy of cancer in animals and man.

Authors:  S A Rosenberg; W D Terry
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

4.  Tumor immunity to murine plasma cell tumors. II. Essential role of T lymphocytes in immune response.

Authors:  B T Rouse; M Röllinghoff; N L Warner
Journal:  Eur J Immunol       Date:  1973-04       Impact factor: 5.532

5.  Brief communication: In vivo protection against murine plasma cell tumor growth by in vitro activated syngeneic lymphocytes.

Authors:  M Röllinghoff; H Wagner
Journal:  J Natl Cancer Inst       Date:  1973-10       Impact factor: 13.506

6.  Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors.

Authors:  H Borberg; H F Oettgen; K Choudry; E J Beattie
Journal:  Int J Cancer       Date:  1972-11       Impact factor: 7.396

7.  Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.

Authors:  J R Berenson; A B Einstein; A Fefer
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

8.  Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro.

Authors:  A J Treves; I R Cohen; M Feldman
Journal:  J Natl Cancer Inst       Date:  1975-03       Impact factor: 13.506

9.  Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.

Authors:  M A Cheever; P D Greenberg; A Fefer
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

10.  Monoclonal cytolytic T-cell lines.

Authors:  P E Baker; S Gillis; K A Smith
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307
View more
  9 in total

1.  Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.

Authors:  M Saito; O Ichimura; M Kataoka; Y Moriya; K Ueno; Y Sugawara; M Nanjo; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  In vivo and in vitro synergistic antitumor effect of interleukin-2-cultured tumor-bearer spleen cells and immune fresh spleen cells.

Authors:  N Kan; T Okino; M Nakanishi; K Satoh; K Ohgaki; T Tobe
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Authors:  S E Ettinghausen; S A Rosenberg
Journal:  Springer Semin Immunopathol       Date:  1986

Review 4.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

5.  Specific adoptive immunotherapy of malignant glioma with long-term cytotoxic T lymphocyte line expanded in T-cell growth factor. Experimental study and future prospects.

Authors:  T Yamasaki; H Handa; J Yamashita; Y Watanabe; Y Namba; M Hanaoka
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

6.  Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor.

Authors:  T Kitahara; O Watanabe; A Yamaura; H Makino; T Watanabe; G Suzuki; K Okumura
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

7.  Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease.

Authors:  R R Salup; R H Wiltrout
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.

Authors:  N Kan; K Ohgaki; T Inamoto; H Kodama
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  The in vivo anti-tumor effect of human recombinant interleukin-6.

Authors:  M Kitahara; S Kishimoto; T Hirano; T Kishimoto; M Okada
Journal:  Jpn J Cancer Res       Date:  1990-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.